Novo Nordisk (NVO)
(Delayed Data from NYSE)
$131.54 USD
+1.55 (1.19%)
Updated Jul 19, 2024 04:00 PM ET
After-Market: $131.58 +0.04 (0.03%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth B Momentum B VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
NVO 131.54 +1.55(1.19%)
Will NVO be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for NVO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NVO
Should Viking (VKTX) Stock be in Your Portfolio Pre-Q2 Earnings?
Novo Nordisk, Lilly Slide on Roche's Obesity Drug Study Data
NVO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Zacks Industry Outlook Eli Lilly, Novo Nordisk, Merck and Pfizer
Roche (RHHBY) Reports Positive Phase I Data on Obesity Drug
Novo Nordisk (NVO) Stock Drops Despite Market Gains: Important Facts to Note
Other News for NVO
Kamala Harris' potential impact on health care stocks
Here are Big Pharma’s leading blockbuster makers
Viking Therapeutics: Great Clinical Results Do Not Guarantee Commercialization Success
Craze For Ozempic And Zepbound For Weight Loss Leave Diabetic Patients Without Critical GLP-1 Medications
Novo Nordisk Options Trading: A Deep Dive into Market Sentiment